42 recruiting in this ClinicalTrials.gov snapshot · reviewed 2026-08-17
Prostate cancer trials range from active surveillance and focal therapy to hormone-sensitive and castration-resistant disease. Many records mention PSMA imaging or androgen-pathway drugs. Read the official NCT page for stage, prior treatment, and PSA rules before you contact a site. Sourced from ClinicalTrials.gov. Not a recommendation to join any study.
Each headline is a rewrite of registry fields (phase, intervention, condition). Open the NCT link before you call a site. Eligibility is decided by the study team, not by this page. See how to find a trial and eligibility explained.
Phases in this snapshot: Not a traditional drug phase (20) · Phase 2 (12) · Phase 1 / Phase 2 (5) · Phase 1 (4) · Early phase 1 (1)
Intervention hubs that overlap this snapshot: Tirzepatide · Pembrolizumab · Nivolumab · Psilocybin · CAR-T therapy · Dapagliflozin
This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate.
NCT00034216 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)
This study will investigate what causes hereditary leiomyomatosis renal (kidney) cell cancer, or HLRCC, and how the disease is related to the development of kidney tumors. Leiomyomas are benign (non-cancerous) tumors arising from smooth muscle.
NCT00050752 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)
This study aims to provide long-term follow-up care of patients previously enrolled in a vaccine study that involved poxviral vectors. Vectors are sequences of genetic material that can be used to introduce specific genes into genetic makeup.
NCT00451022 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)
Background: * It is not fully understood why prostate cancer in some men becomes androgen-independent (no longer responds to anti-androgen medication), but genetics likely plays an important role. * Genes contain the hereditary information that is passed down from parents to children.
NCT00923221 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)
Background: \- Radiation is a common treatment for prostate cancer. It helps damage tumor cells and causes them to die.
NCT01834001 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)
Background: Prostate cancer is the most common noncutaneous cancer among men in the U.S. Researchers want to study blood, tissue, and fluid samples of people with prostate cancer.
NCT02594202 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT03866382 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)
The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The goal of Part 1 (dose escalation) is to determine a safe dose(s) of REGN5678 when it is given alone or in combination with cemiplimab.
NCT03972657 · Official ClinicalTrials.gov record · Regeneron Pharmaceuticals
Diffusion Basis Spectrum Imaging (DBSI) represents a potential leap forward in improving prostate cancer early detection: a non-invasive and accurate imaging test for clinically significant prostate cancer.
NCT04420702 · Official ClinicalTrials.gov record · Washington University School of Medicine
This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and in combination with endocrine therapy. Part 1 includes dose escalation cohorts evaluating PF-07220060 as single agent or in combination with endocrine therapy or enzalutamide, as well as a food effect cohort and a DDI cohort.
NCT04557449 · Official ClinicalTrials.gov record · Pfizer
This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical how well it works of PF-07248144 as a single agent and in combination with other agents
NCT04606446 · Official ClinicalTrials.gov record · Pfizer
This study aims to define the natural history of men at high genetic risk for prostate cancer on the basis of specific germline genetic mutations, family history, or Black/African ancestry and measure the utility of prostate MRI as a screening tool. The hypothesis is that this targeted population of men are at elevated risk of developing prostate cancer compared to the general population, and enhanced screening with MRI will enable early detection and diagnosis of potentially aggressive prostate cancer, characterization of the penetrance of specific mutations, and potentially identify new genetic risk mutations.
NCT05129605 · Official ClinicalTrials.gov record · Massachusetts General Hospital
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.
NCT05334069 · Official ClinicalTrials.gov record · Alliance for Clinical Trials in Oncology
This is an watch-and-measure (no experimental treatment required) case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid.
NCT05366881 · Official ClinicalTrials.gov record · Adela, Inc
The aim of this study is to assess the progression free survival (PFS) of SABR alone and SABR + 177Lu-prostate-specific membrane antigen (PSMA) in patients with oligometastatic prostate cancer undergoing PSMA positron emission tomography (PET) staging.
NCT05560659 · Official ClinicalTrials.gov record · Peter MacCallum Cancer Centre, Australia
Background: Prostate cancer is the second leading cause of cancer-related death in American men. The disease recurs in up to 50,000 men each year after their early-stage disease was treated; however, at this stage, imaging scans are often unable to find the disease in the body.
NCT05588128 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)
This phase Ib trial tests the safety, side effects, and best dose of autologous anti-prostate stem cell antigen (PSCA)-chimeric antigen receptor (CAR)-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes (PSCA-CAR T cells), plus or minus radiation, in treating patients with castration-resistant prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Castration-resistant prostate cancer continues to grow and spread despite the surgical removal of the testes or medical intervention to block androgen production.
NCT05805371 · Official ClinicalTrials.gov record · City of Hope Medical Center
In this project, we will integrate the Photoacoustic (PA) technology into a prostate biopsy procedure through a fine needle probe. The needle probe will be in the shape of a biopsy needle and compatible with the needle insertion mechanism in the transrectal ultrasound (TRUS) probe.
NCT05965180 · Official ClinicalTrials.gov record · University of Michigan Rogel Cancer Center
Background: Men who are treated for prostate cancer often develop urinary leakage (incontinence). An experimental device that uses electrical impulses to stimulate pelvic floor muscles and surrounding tissues may help.
NCT06161506 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)
This study is to investigate the how well it works of Targeted Microwave Ablation (TMA) under MRI-Ultrasound fusion and organ-based tracking (OBT) navigation in localized prostate cancer (PCa) in a multi-centre trial.
NCT06262633 · Official ClinicalTrials.gov record · Chinese University of Hong Kong
This study wants to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion).
NCT06465069 · Official ClinicalTrials.gov record · Eli Lilly and Company
The goal of this clinical research study is to determine how well a tirzepatide-assisted weight loss program works before a prostatectomy in patients with intermediate risk prostate cancer
NCT06759701 · Official ClinicalTrials.gov record · M.D. Anderson Cancer Center
This is a study using a self-control approach and is expected to recruit 35 volunteers, including prostate cancer patients, neuroendocrine tumour patients, glioma patients, lung cancer patients, and normal volunteers, to undergo dual-tracer PET/CT imaging and to validate the separation performance and quantitative accuracy of simultaneous dual-tracer imaging in humans.
NCT06914427 · Official ClinicalTrials.gov record · Xijing Hospital
This research is being done to determine if receiving the combination of testosterone and ZEN-3694 followed by the combination of enzalutamide plus ZEN-3694 will decrease the size of tumors in patients with prostate cancer that has become resistant to castration and other therapies. The investigators also want to determine if dosing first with the combination of testosterone and ZEN-3694 may cause enzalutamide and ZEN-3694 to work more effectively.
NCT06922318 · Official ClinicalTrials.gov record · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home. Treatments for cancer can cause side effects such as fatigue and loss of strength.
NCT07059884 · Official ClinicalTrials.gov record · Alliance for Clinical Trials in Oncology
This study is assessing the how well it works and safety of NPX-5 in psilocybin-assisted psychotherapy for the treatment of adjustment disorder due to cancer diagnosis. This study is for people who are aged between 18 and 80 years old and suffer from anxiety after adjusting to an acutely stressful event of their cancer diagnosis.
NCT07072728 · Official ClinicalTrials.gov record · Psyence Australia Pty Ltd
This phase II trial evaluates the impact of cancer therapy in the patients' home compared to in the clinic on safety, side effects, patient preference, and satisfaction in Black men with prostate cancer that has spread to nearby tissue or lymph nodes (locally advanced), that has increasing prostate-specific antigen after treatment (biochemically recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Typically drug-related cancer care is conducted at a medical center which causes patients to have to spend considerable time away from family, friends, and familiar surroundings.
NCT07073794 · Official ClinicalTrials.gov record · Mayo Clinic
This study wants to evaluate intermittent relugolix + androgen receptor pathway inhibitor (ARPI) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) achieving optimal PSA response.
NCT07216248 · Official ClinicalTrials.gov record · University of Utah
This prospective, non-therapeutic translational biomarker study will collect blood in patients with high risk localized prostate cancer prior to prostatectomy.
NCT07222436 · Official ClinicalTrials.gov record · University of Pittsburgh
This study will measure the how well it works and safety of the combination of inavolisib plus enzalutamide compared with physician's choice of alternative androgen receptor pathway inhibitor (ARPi) or docetaxel in biomarker-selected participants with metastatic castrate-resistant prostate cancer (mCRPC) who have received one prior second-generation ARPi.
NCT07287150 · Official ClinicalTrials.gov record · Hoffmann-La Roche
One of the most relevant targets in the field of novel targeted anticancer therapy is the family of receptors to fibroblast growth factor receptors (FGFRs). FGFR1 is the main representative of the FGFR family.
NCT07292168 · Official ClinicalTrials.gov record · Kidney Cancer Research Bureau
Dapagliflozin is a well-established medication being marketed and used for treatment Type 2 diabetes mellitus (T2DM). In retrospective cohort studies done by our team, we found that metastatic prostate cancer patients who received Dapagliflozin together with standard anti-cancer treatment, androgen deprivation therapy (ADT) combined with novel hormonal agent (NHA), had better tumor control than those having ADT and NHA.
NCT07310433 · Official ClinicalTrials.gov record · Yung NA
This first-time-in-human study will measure the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit/risk of GSK5471713 given as a this drug alone in mCRPC.
NCT07332455 · Official ClinicalTrials.gov record · GlaxoSmithKline
The goal of this clinical trial is to find out whether lowering the radiation dose to parts of the prostate without visible tumor on MRI can reduce side effects while still effectively treating prostate cancer in men with low or intermediate-risk prostate cancer. The main questions it aims to answer are: * Does reducing the radiation dose to healthy prostate tissue lower the risk of bowel and urinary side effects?
NCT07391982 · Official ClinicalTrials.gov record · The Netherlands Cancer Institute
The study consists of Phase 1a (dose escalation) and Phase 1b (dose expansion). In Phase 1a, sequential cohorts of subjects will receive escalating doses of ITC-6146RO to determine maximum tolerated dose (MTD) and/or optimal biological dose (OBD).
NCT07423117 · Official ClinicalTrials.gov record · IntoCell, Inc
This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to measure the safety, PK, immunogenicity and preliminary how well it works of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.
NCT07503808 · Official ClinicalTrials.gov record · IDEAYA Biosciences
Background: Prostate cancer is the second most common cause of cancer-related death among men in the United States. Early-stage, low-grade prostate cancer is managed with active monitoring.
NCT07574541 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)
The WATER IV study is a multicenter, prospective, randomly assigned clinical trial that aims to measure the safety and how well it works of Aquablation therapy in men with localized prostate cancer.
NCT07650448 · Official ClinicalTrials.gov record · PROCEPT BioRobotics
Background: Head and neck cancers (HNCs) account for about 5% of all cancers worldwide. They grow in the mouth, throat, nasal cavity, or salivary glands.
NCT07667400 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)
This study is being done at Duke Health and includes adult men who have been treated for localized prostate cancer. The goal is to see if it is feasible and acceptable to offer sex therapy by telehealth after prostate cancer treatment.
NCT07685249 · Official ClinicalTrials.gov record · Duke University
The purpose of this clinical trial is to measure the safety, tolerability, and preliminary anti-cancer activity of GI-102 in combination with pasritamig in adult men with metastatic castration-resistant prostate cancer (mCRPC) whose cancer has progressed after previous treatment with a novel hormonal therapy (NHT).
NCT07871435 · Official ClinicalTrials.gov record · GI Innovation, Inc.
This study aims to measure the feasibility, safety, and diagnostic performance of 68Ga-XMFH01, a novel ACP3-targeted dual-modality PET and fluorescence imaging probe, for preoperative PET/CT imaging and intraoperative fluorescence-guided surgery in patients with prostate cancer.
NCT07885423 · Official ClinicalTrials.gov record · The First Affiliated Hospital of Xiamen University
This hub lists 42 recruiting Prostate cancer studies from a ClinicalTrials.gov snapshot, rewritten in plain English. Each card links to its NCT record. You can also search the official registry for “prostate cancer” at https://clinicaltrials.gov/search?cond=prostate%20cancer.
A phase explainer, a plain-English summary grounded in the brief summary, inclusion/exclusion extracted from the public eligibility block, sponsor name, and any central contact the sponsor published. It is not a match to a trial.
Sites that appear on these records include Las Vegas, Nevada; Henderson, Nevada; Columbus, Ohio; Anchorage, Alaska; New York, New York. A city on a record is not a guarantee that the site is taking new patients this week — call the NCT contact.
No. Eligibility is decided by the study team using the protocol, labs, and consent. Our “who it is for” list is a readable extract of public inclusion text only.
Trials testing new drugs, antibody therapies, surgery timing, and radiation approaches.
Immunotherapy, targeted pills for EGFR/ALK, and early-detection studies.
Immunotherapy, targeted drugs, and surgery-timing studies for colon and rectal cancer.
Chemotherapy combinations, KRAS-targeted drugs, and earlier-detection studies.
Checkpoint drugs, TIL therapy, and adjuvant studies after surgery.
PARP inhibitors, antibody-drug conjugates, and maintenance after platinum therapy.